Teva Files 2012 Annual Report on Form 20-F
JERUSALEM -- March 8, 2013
In accordance with Section 203.01 of the New York Stock Exchange Listed
Company Manual, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced
today that it has filed its 2012 Annual Report on Form 20-F with the U.S.
Securities and Exchange Commission. The Annual Report can be found on the
company’s website at www.tevapharm.com as well as on the SEC website at
www.sec.gov. In addition, security holders may request a hard copy of the
Annual Report, which includes the company’s complete audited financial
statements, free of charge. Requests can be made by contacting Teva Investor
Relations at 1090 Horsham Road, North Wales PA, 19454 or by phone at (215)
591-8912 or 011-972-3-926-7656.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's leading generic drug
maker, with a global product portfolio of more than 1,000 molecules and a
direct presence in about 60 countries. Teva's branded businesses focus on CNS,
oncology, pain, respiratory and women's health therapeutic areas as well as
biologics. Teva currently employs approximately 46,000 people around the world
and reached $20.3 billion in net revenues in 2012.
Teva Pharmaceutical Industries Ltd.
Kevin C. Mannix, 215-591-8912
Kristen Frank, 215-591-8908
Tomer Amitai, 972 (3) 926-7656
Hadar Vismunski-Weinberg, 972 (3) 926-7687
Denise Bradley, 215-591-8974
Press spacebar to pause and continue. Press esc to stop.